NEJM January 22,2026 Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

This Week In Medicine · Jan 23, 2026 · 9m

This clinical study investigates a promising new treatment combination for patients facing advanced triple-negative breast cancer, a particularly aggressive form of the disease. Researchers compared the effectiveness of pairing the drug sacituzumab govitecan with pembrolizumab against the standard approach of using traditional chemotherapy with immunotherapy. The trial found that patients receiving the new combination therapy experienced a significantly longer duration of progression-free survival, maintaining stability for over eleven months on average. Beyond just slowing the disease, this…